ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect. The company is developing a bio-selected RNA virus to induce tumour inflammation and achieve immune cell infiltration via the RIG-I pathway. The targets for this approach are Ovarian, Head & Neck and those indications which present with liver metastases such as Colorectal, Hepatocellular carcinoma and Pancreatic cancer. The approach includes combination therapy with Immune Checkpoint Inhibitors and CAR-T agents using bio-selected RNA virus. The company founders, Malcolm McColl and Prof. Darren Shafren, were Managing Director and CSO of Viralytics, an ASX listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million. The ImmVirX team includes key management and researchers from Viralytics and is based at the former Viralytics laboratory facilities in Newcastle Australia.
Location: Australia, New South Wales, Newcastle
Employees: 11-50
Founded date: 2019
Investors 1
| Date | Name | Website |
| 29.07.2023 | OneVenture... | one-ventur... |
Mentions in press and media 1
| Date | Title | Description | Source |
| - | ImmVirX | “ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients wi... | fastfounde... |